Pharma Mar, S.A. (LON:0RC6)

Market Cap	1.14B -14.1%
Revenue (ttm)	156.48M +7.3%
Net Income	29.68M +5,367.0%
EPS	1.70
Shares Out	n/a
PE Ratio	38.34
Forward PE	25.39
Dividend	0.68 (0.89%)
Ex-Dividend Date	Jun 25, 2025

Volume	184
Average Volume	562
Open	76.05
Previous Close	76.40
Day's Range	74.65 - 77.10
52-Week Range	65.05 - 105.60
Beta	0.44
RSI	44.91
Earnings Date	Feb 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata for the treatment of soft tissue sarcoma and recurrent ovarian cancer; Aplidin ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RC6

Financial Performance

In 2024, Pharma Mar's revenue was 174.86 million, an increase of 10.56% compared to the previous year's 158.15 million. Earnings were 26.13 million, an increase of 2197.71%.

Financial numbers in EUR